Bayer Aktiengesellschaft (ETR:BAYN)
27.78
+0.20 (0.71%)
Oct 24, 2025, 5:35 PM CET
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 10.74B EUR in the quarter ending June 30, 2025, a decrease of -3.63%. This brings the company's revenue in the last twelve months to 46.17B, down -1.99% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
46.17B
Revenue Growth
-1.99%
P/S Ratio
0.59
Revenue / Employee
515.59K
Employees
91,864
Market Cap
27.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.28B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.52B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.68B |
| Fielmann Group AG | 2.40B |
| Carl Zeiss Meditec AG | 2.18B |
Bayer Aktiengesellschaft News
- 2 days ago - Bayer Wins FDA Approval for Menopause Drug Treating Hot Flashes - Financial Post
- 2 days ago - US FDA approves Bayer's menopause relief drug - Reuters
- 2 days ago - Bayer’s Lynkuet (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause - Wallstreet:Online
- 2 days ago - Bayer's Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause - Business Wire
- 5 days ago - Top 3 Health Care Stocks You'll Regret Missing In October - Benzinga
- 6 days ago - Bayer Leverkusen vs PSG: Head-to-head, match preview, predicted lineups and score prediction - Business Upturn
- 17 days ago - BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers - Nasdaq
- 17 days ago - Why Bayer's Worst Years Might Be The Start Of Its Comeback - Seeking Alpha